Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects
Study identifier:MB102-059
ClinicalTrials.gov identifier:NCT00908271
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects
Medical condition
Type 2 Diabetes Mellitus
Phase
Phase 1
Healthy volunteers
Yes
Study drug
Dapagliflozin
Sex
Male
Actual Enrollment
7
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Jul 2009
Primary Completion Date: 01 Aug 2009
Study Completion Date: 01 Aug 2009
Study design
Allocation: N/A
Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other
Verification:
Verified 01 Oct 2016 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
Bristol-Myers Squibb
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Other: Dapagliflozin PO and IV | Drug: Dapagliflozin Tablet and IV solution, Oral and IV, 10 mg po and 100 µg IV, Single oral dose followed by a single IV dose (IV dose administered at 1h after oral dose), 1 day |
Contacts
Contact
AstraZeneca Clinical Study Information Center
Investigators
Principal Investigator
Bristol-Myers Squibb
Bristol-Myers Squibb
